BiotechTube

Satralizumab + Placebo + Baseline Treatment

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica (NMO)

Conditions

Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)

Trial Timeline

Feb 20, 2014 → Dec 23, 2021

NCT ID
NCT02028884

About Satralizumab + Placebo + Baseline Treatment

Satralizumab + Placebo + Baseline Treatment is a phase 3 stage product being developed by Chugai Pharmaceutical for Neuromyelitis Optica (NMO). The current trial status is completed. This product is registered under clinical trial identifier NCT02028884. Target conditions include Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD).

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02028884Phase 3Completed

Competing Products

8 competing products in Neuromyelitis Optica (NMO)

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
85
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
77
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
77
SatralizumabRochePhase 3
77
UPLIZNAAmgenPre-clinical
22
InebilizumabAmgenPhase 2
51
InebilizumabAmgenApproved
84
intravenous methylprednisoloneBrain BiotechPre-clinical
15

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77